Related Experiment Video
Updated: Jul 8, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in
Coleen R Kaiser1, Michelle L Flenniken, Eric Gillitzer
1Department of Veterinary Molecular Biology, Montana State University, Bozeman, Montana, USA.
Abstract:
Protein cage nanoparticles have the potential to serve as multifunctional cell targeted, imaging and therapeutic platforms for broad applications in medicine. However, before they find applications in medicine, their biocompatibility in vivo needs to be demonstrated. We provide here baseline biodistribution information of two different spherical protein cage nanoplatforms, the 28 nm viral Cowpea chlorotic mottle virus (CCMV) and the 12 nm heat shock protein (Hsp) cage. In naive and immunized mice both nanoplatforms show similar broad distribution and movement throughout most tissues and organs, rapid excretion, the absence of long-term persistence within mice tissue and organs, and no overt toxicity after a single injection. These results suggest that protein cage based nanoparticles may serve as safe, biocompatible, nanoplatforms for applications in medicine.
Related Concept Videos
Drug Distribution: Tissue Binding
For...
Drug Distribution: Plasma Protein Binding
Physiological Pharmacokinetic Models: Assumption with Protein Binding
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Measurement of Bioavailability: Pharmacokinetic Methods

